Customize your JAMA Network experience by selecting one or more topics from the list below.
Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ. Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts. JAMA. 2014;312(1):90–92. doi:10.1001/jama.2014.5804
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Sepsis, the inflammatory response to infection, affects millions of patients worldwide.1 However, its effect on overall hospital mortality has not been measured. We quantified the contribution of sepsis to mortality in 2 complementary inpatient cohorts from Kaiser Permanente Northern California (KPNC) and the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (NIS).
The KPNC cohort included 482 828 adults (aged ≥18 years) with overnight, nonobstetrical hospitalizations at 21 KPNC hospitals between 2010 and 2012.2 Compared with all Northern California patients, KPNC patients have broadly similar health characteristics but higher income and educational attainment.3 The NIS, a nationally representative sample of 1051 hospitals, included 6.5 million unweighted adult hospitalizations in 2010.4
We used 2 approaches to identify patients with sepsis from International Statistical Classification of Diseases, Ninth Revision, Clinical Modification codes. The explicit approach identified those with codes 038 (septicemia), 995.91 (sepsis), 995.92 (severe sepsis), or 785.52 (septic shock). Because of the known underrecognition of sepsis, we also used an implicit approach adding patients with evidence of both infection and acute organ failure using the Angus implementation5 of sepsis consensus criteria. Within KPNC data, we delineated diagnoses when coded as present on admission, an important consideration for improving identification and treatment efforts. Furthermore, we linked 97.9% (n = 19 621) of all explicit sepsis cases present on admission in 2012 to KPNC quality improvement data, permitting stratification of patients by common sepsis severity criteria including early goal-directed therapy (EGDT) eligibility and serum lactate levels.6
In each cohort, we calculated the percentage of all inpatients admitted with sepsis, the sepsis hospital mortality rate, and the percentage and 95% confidence interval of hospital deaths occurring in patients with sepsis using Stata version 11.2 (StataCorp). The KPNC institutional review board approved the use of KPNC data with a waiver of informed consent and exempted NIS data from review.
In the KPNC cohort, there were between 55 008 explicit (11.4% of total; 95% CI, 11.3%-11.5%) and 80 678 implicit (16.7%; 95% CI, 16.6%-16.8%) sepsis hospitalizations (Table 1); most occurrences of sepsis were present on admission. From the NIS cohort, 280 663 (4.3%; 95% CI, 4.3%-4.3%) hospitalizations met explicit sepsis criteria while 717 718 (10.9%; 95% CI, 10.9%-11.0%) met implicit criteria.
Of 14 206 KPNC inpatient deaths, 36.9% (95% CI, 36.1%-37.7%; explicit) to 55.9% (95% CI, 55.1%-56.7%; implicit) occurred among patients with sepsis, which was nearly all present on admission. Of 143 312 NIS deaths, 34.7% (95% CI, 34.4%-34.9%; explicit) to 52.0% (95% CI, 51.7%-52.2%; implicit) occurred among patients with sepsis. In the 2012 linked KPNC subset (Table 2), patients with sepsis meeting criteria for EGDT (n = 2536) comprised 32.6% (95% CI, 30.4%-34.7%) of sepsis deaths. In contrast, patients with sepsis, normal blood pressure, and measured lactate levels of less than 4 mmol/L (n = 15 095) comprised 55.9% (95% CI, 53.6%-58.1%) of sepsis deaths.
In 2 complementary hospital cohorts, we found that sepsis contributed to 1 in every 2 to 3 deaths, and most of these patients had sepsis at admission. Given the prominent role it plays in hospital mortality, improved treatment of sepsis (potentially a final hospital pathway for multiple other underlying conditions) could offer meaningful improvements in population mortality.
Patients with initially less severe sepsis made up the majority of sepsis deaths. Performance improvement efforts in the treatment of sepsis have primarily focused on standardizing care for the most severely ill patients, whereas interventions for treating other patients with sepsis are less well defined. Given their prevalence, improving standardized care for patients with less severe sepsis could drive future reductions in hospital mortality.
Even though our findings were broadly consistent, the study’s primary limitation results from potential inaccuracies and inconsistencies in case identification across cohorts. Prior strategies, based on administrative data, have demonstrated variability with respect to prevalence estimates and case accuracy, a factor that may have contributed to differences between cohorts in explicit sepsis mortality.5 Thus, we present granular data from the KPNC sepsis quality improvement program whose components include standardized case identification, manual chart validation, severity of illness risk adjustment, and treatment data; replication in other samples with similar granularity could be valuable.
Corresponding Author: Vincent Liu, MD, MS, 2000 Broadway, Oakland, CA 94612 (email@example.com).
Published Online: May 18, 2014. doi:10.1001/jama.2014.5804.
Author Contributions: Dr Liu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Liu, Escobar, Soule, Whippy.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Liu.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Liu, Greene, Iwashyna.
Obtained funding: Liu, Escobar, Iwashyna.
Administrative, technical, or material support: Liu, Escobar, Soule.
Study supervision: Angus.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Angus reported receiving nonfinancial support from Edwards Inc; personal fees from Pfizer, MedImmune LLC, Eli Lilly, Ferring Pharmaceuticals, and Roche Diagnostics International Ltd; and a grant from Eisai Inc. No other disclosures were reported.
Funding/Support: This work was supported by the Permanente Medical Group, the Kaiser Foundation Hospitals and Health Plan, the Gordon and Betty Moore Foundation, and US Department of Veterans Affairs Health Services Research & Development grant IIR 11-109.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.
Disclaimer: Dr Angus, associate editor for JAMA, was not involved in the editorial review of or decision to publish this article.